Notes
What I think about while working.
One or more articles a month, no editorial calendar. Published here first, shared on LinkedIn after.
Only 1% of trials involve AI, and who is behind them
The number people will share is 1%. The part worth reading is who signs those studies: hospitals and universities, not industry.
ReadEmulatRx: five agents designing a clinical trial
A multi-agent system that designs trials from real-world data. How this architecture will reach clinical research: task by task, not as one product.
ReadRolling out AI in an SME: provider, plan, license
Three decisions, in this order. Most of the complexity in an AI rollout is in the pricing pages, not in the decision itself.
Read